Three-dimensional cultures (or “organoids”) derived from the tumors of cancer patients closely replicate key properties of the original tumors, reveals a study published May 7 in Cell. These “organoid” cultures are amenable to large-scale drug screens for the detection of genetic changes associated with drug sensitivity and pave the way for personalized treatment approaches that could optimize clinical outcomes in cancer patients.
“This is the first time that a collection of cancer organoids, or a living biobank, has been derived from patient tumors,” says senior study author Mathew Garnett, a geneticist at the Wellcome Trust Sanger Institute. “We believe that these organoids are an important new tool in the arsenal of cancer biologists and may ultimately improve our ability to develop more effective cancer treatments.”
To study the causes of cancer and develop new cancer treatments, many laboratories use experimental model systems such as cells grown from patient tumors. However, currently available cell lines have been derived under suboptimal conditions and therefore fail to reflect important features of tumor cells. As a result, it has been challenging to predict the drug sensitivity of individual patients based on their unique spectrum of genetic mutations.
In recent years, scientists have developed organoid cell culture systems as an alternative approach to grow normal and diseased tissue in a dish. In contrast to cell lines, organoids display the hallmarks of the original tissue in terms of its 3D architecture, the cell types present, and their self-renewal properties. Given the advantages of organoids, Garnett and Hans Clevers of the Hubrecht Institute set out to test whether these cultures could potentially bridge the gap between cancer genetics and patient outcomes.
In the new study, the researchers grew 22 organoids derived from tumor tissue from 20 patients with colorectal cancer and then sequenced genomic DNA isolated from these cultures. The genetic mutations in the organoid cultures closely matched those in the corresponding tumor biopsies and agreed well with previous large-scale analyses of colorectal cancer mutations. These findings confirm that the cultures faithfully capture the genomic features of the tumors from which they are derived as well as much of the genomic diversity associated with colorectal cancer.
To link drug sensitivity to genetic changes, the researchers next screened the responses of the organoids to 83 experimental and approved cancer drugs. Given their diverse genetic profiles, the organoids displayed a range of sensitivities to the drugs. In validation of the approach, the researchers identified previously reported associations between specific mutations and resistance to particular drugs. The organoids also revealed a novel gene-drug association, indicating that the subset of cancer patients with RNF43 mutations would strongly benefit from a drug that inhibits a protein called porcupine. “At some point in the future, this approach may be suitable for modeling individual patient response to cancer therapies to inform clinical treatment,” Garnett says.
The Latest on: Organoids
via Google News
The Latest on: Organoids
- Preliminary analysis of xenograft versus organoidson November 10, 2020 at 9:43 pm
The observance of Lung Cancer Awareness Month in November affords an opportunity to take stock of current approaches to lung cancer research, and to cancer research more widely.
- Heart Organoids Mimic the Early Stages of Embryonic Heart Developmenton November 10, 2020 at 4:00 pm
Bioengineers at EPFL have used organoids to mimic the early development of the heart in the mouse embryo. The work is another step towards future bioartificial organs for research and transplants.
- Organoids produce embryonic hearton November 10, 2020 at 8:04 am
There was a time when the idea of growing organs in the lab was the stuff of science fiction. Today, stem cell biology and tissue engineering are turning fiction into reality with the advent of ...
- Midbrain organoids developed for automated chemical screeningon November 5, 2020 at 3:58 am
Researchers have used small molecule neural precursor cells to develop midbrain organoids that enable drug effects to be assessed in cells.
- Sales of Organoids to Decelerate in 2020 as COVID-19 Pandemic Takes Its Toll on Global Marketon November 4, 2020 at 10:40 am
Organoids Market Pushing the Disease-fighting Potential of Biopharmaceuticals. This press release was orginally distributed by SBWire. Valley Cottage, NY -- -- 11/04/2020 -- Organ ...
- Spheroids, Organoids Replacing Standard Cultures for Cell-Based Assayson November 3, 2020 at 7:58 am
D cultures involve significantly more attention and resources to get right, as opposed to the simple 2D plating of cells. Adopting spheroids or organoids in a drug screening program also requires a ...
- Midbrain organoids for automated chemical screening and disease researchon November 3, 2020 at 3:37 am
Bruder, Group leader [email protected] Max Planck Institute for Molecular Biomedicine, Münster A fully automated high-throughput workflow for 3D-based chemical screening in human midbrain ...
- Lung stem cell organoids developed to study COVID-19on November 2, 2020 at 9:19 am
Two teams of researchers have successfully grown 3D lung models to study the progression of COVID-19. The models allow researchers to study the infection of lung cells with SARS-CoV-2, the virus which ...
- A groundbreaking genetic screening tool for human organoidson October 29, 2020 at 2:15 pm
Researchers have developed CRISPR-LICHT, a revolutionary technology that allows genetic screens in human tissues such as brain organoids. By applying the novel technology to brain organoids ...
- Organoids Can Grow Faster by Compressing Cellson October 14, 2020 at 5:40 pm
To see whether cell squeezing affects the Wnt pathway, and how fast a cell grows, the researchers grew small organoids, i.e., miniature organs, and in this case, clusters of cells that were ...
via Bing News